Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Assets Average: 2020-2025

Historic Assets Average for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to $1.1 billion.

  • Kymera Therapeutics' Assets Average rose 20.00% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 20.00%. This contributed to the annual value of $776.9 million for FY2024, which is 31.80% up from last year.
  • Per Kymera Therapeutics' latest filing, its Assets Average stood at $1.1 billion for Q3 2025, which was up 8.97% from $1.0 billion recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Assets Average peaked at $1.1 billion during Q3 2025, and registered a low of $449.5 million during Q2 2021.
  • Over the past 3 years, Kymera Therapeutics' median Assets Average value was $847.1 million (recorded in 2024), while the average stood at $812.1 million.
  • Its Assets Average has fluctuated over the past 5 years, first fell by 9.14% in 2023, then spiked by 78.42% in 2024.
  • Over the past 5 years, Kymera Therapeutics' Assets Average (Quarterly) stood at $624.2 million in 2021, then dropped by 0.54% to $620.8 million in 2022, then dropped by 9.14% to $564.1 million in 2023, then skyrocketed by 78.42% to $1.0 billion in 2024, then increased by 20.00% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $1.0 billion for Q2 2025, and $948.2 million during Q1 2025.